Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial.
Lars Eckardt, Susanne Sehner, Anna Suling...
https://pubmed.ncbi.nlm.nih.gov/36036648/Actively Recruiting
Led by Atrial Fibrillation Network · Updated on 2026-01-08
2312
Participants Needed
7
Research Sites
12 weeks
Total Duration
Researchers are investigating whether early atrial fibrillation ablation reduces cardiovascular events in patients with atrial fibrillation who have a high burden of other health problems, measured by a CHA2DS2-VASc score of 4 or more. This is an international, randomized, open trial designed to compare early ablation with usual care to see if it lowers risks of stroke, cardiovascular death, or heart failure events. The study also looks at safety, patient-reported outcomes, and cognitive function in this population. Participants are randomly assigned to one of two groups one group undergoes early atrial fibrillation ablation, specifically pulmonary vein isolation within two months of randomization, while the other group receives usual care following guideline-based treatments tailored to their individual medical needs. All treatments involved are approved therapies. The trial aims to enroll 2312 patients and will continue until a set number of cardiovascular events have occurred, with an estimated average follow-up of about four years. During the study, researchers will monitor cardiovascular complications including death, stroke, and hospitalizations related to heart failure. They will also track serious complications from atrial fibrillation therapy and assess quality of life, heart function, rhythm status, cognitive function, and hospital stays over the follow-up period. Patients will be regularly evaluated for both safety and effectiveness outcomes throughout the study duration.
CONDITIONS
Early Atrial Fibrillation Ablation for Stroke Prevention in Patients With High Comorbidity Burden (EASThigh-AFNET 11)
A
Antje Albring, Dr.
A
Anna-Katharina Quade
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Atrial Fibrillation Network
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 4 years
Participants receive either early atrial fibrillation ablation within 2 months after randomization or usual care based on guideline recommendations and local protocols.
Regular visits according to clinical care and study follow-up schedule
Duration - Up to 4 years
Participants are monitored for cardiovascular events, safety outcomes, quality of life, cognitive function, and cardiac rhythm status after treatment.
Follow-up visits at 12 and 24 months, with ongoing monitoring throughout study completion
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Lars Eckardt, Susanne Sehner, Anna Suling...
https://pubmed.ncbi.nlm.nih.gov/36036648/Paulus Kirchhof, A John Camm, Andreas Goette...
https://pubmed.ncbi.nlm.nih.gov/32865375/Jason G Andrade, Marc W Deyell, Laurent Macle...
https://pubmed.ncbi.nlm.nih.gov/36342178/Andreas Rillig, Katrin Borof, Günter Breithardt...
https://pubmed.ncbi.nlm.nih.gov/35968706/Jannis Dickow, Paulus Kirchhof, Holly K Van Houten...
https://pubmed.ncbi.nlm.nih.gov/35621202/Jannis Dickow, Shinwan Kany, Victor Roth Cardoso...
https://pubmed.ncbi.nlm.nih.gov/36942567/Jason G Andrade, George A Wells, Marc W Deyell...
https://pubmed.ncbi.nlm.nih.gov/33197159/Atrial Fibrillation Network
Lead Sponsor